It’s being expected that by 2030, the Biochip market cap will hit USD 34.25 Billion at a CAGR growth of about 11.5%.
.jpg
"The Global Biochip Market 2020-2030 (USD Billion)")
In the recent years, biochips have emerged as one of the most groundbreaking technologies in the fields of biotechnology, electronics & computers. Technological advancements in proteomics, genomics & pharmaceuticals have provided researchers with new methods to unravel the complex biochemical processes that occur inside cells, with the wider goal of understanding and treating numerous diseases. Also, the semiconductor industry has been constantly improving the technology of micro-miniaturization almost simultaneously and the combination of these two fields has led to the development of biochips, which allow biotechnologists to start accommodating their bulky sensing tools into smaller devices.
A biochip is the system that can contain millions of individual bio sensors. The packaging of these sensor components over a microscopic slide on a solid substratum allows to perform long tasks with high throughput in a short period of time. Every biochip can be considered as a "micro-reactor", which is capable of sensing a specific analyte. The analyte may be a molecule of DNA, insulin, protein, antibody, or any biological. Hence, a biochip can conduct thousands of biological reactions such as decoding genes, within few seconds.
Growing application of biochip in medical processes of drug research, diagnosis and chronic disease identification and treatment has fared as a significant driving force behind the growth of biochips market. The global biochips market has gained significant prominence in the last decade due to the growing need for faster, more effective and cheaper methods for gene decoding, and biomarker detection. Growing preference for compact and cheaper biochip models can assist in implementing multiple complex protocols for analysis in faster and inexpensive fashion. The global biochips market is anticipated to steadily head towards growth within the considered the forecast period due to growing research funding and investments, increasing preference for animal-free testing and so on.
Biochip Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2030 |
| Study Period | 2018-2030 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2030 | USD 34.25 Billion |
| Growth Rate | CAGR of 11.5 % during 2022-2030 |
| Segment Covered | Technology, Region. |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | bioMerieux SA, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Fluidigm, Illumina, Inc., HORIBA, Ltd., PerkinElmer, Inc., QIAGEN, Randox Laboratories Ltd., and Thermo Fisher Scientific Inc. |
Key segments of the global biochips market
Product Overview, (USD Million)
- DNA Chip
- Protein Chip
- Enzyme Chip
- Lab-on-a-chip
Fabrication Techniques Overview, (USD Million)
- Microarray
- Microfluidics
Analysis Methods Overview, (USD Million)
- Electrophoresis
- Luminescence
- Mass Spectrometry
- Electrical Signals
- Magnetism
Applications Overview, (USD Million)
- Molecular Analysis
- Diagnostics
- Non-Biological Usage
Regional Overview, (USD Million)
- North America
-
- U.S.
- Canada
-
- Europe
-
- UK
- Germany
- France
- Switzerland
- Rest of Europe
-
- Asia Pacific (APAC)
-
- India
- China
- Japan
- Rest of APAC
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa (MEA)
-
- GCC
- Rest of MEA
-
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global biochip industry
- The overall segmentation of biochips market, especially key segments such as product, fabrication techniques, analysis methods, and applications are thoroughly studied. Based on product type, DNA chip holds the maximum market share and is anticipated to continue growth till 2025.
- Presence of major players and their wide product portfolio across developed countries is anticipated to further boost the growth of biochips market
What does the report include?
- The study on the global biochips market includes qualitative analysis of factors such as drivers, restraints, opportunities, and competitive landscape analysis
- Additionally, the market has been evaluated using the industrial value chain analysis comprising upstream and downstream analysis, cost analysis and product type analysis
- The study covers qualitative and quantitative analysis of the overall market segmented on the basis of product, end users and breakdown of the same at regional level
- Actual market sizes and forecasts have been provided for all the considered segments
- The study includes the profiles of key market players with a significant global and/or regional presence along with top company positioning
Who should buy this report?
This study is suitable for industry participants and stakeholders in the Biochip industry, who want an in-depth insight into the movement of the Biochip market. The report will benefit:
- Executives of biochip manufacturing companies that are engaged in spreading knowledge about advantages of biochips
- Managers within financial institutions looking to publish recent and forecasted statistics pertaining to biochips
- Venture capitalists, investors, financial institutions, analysts, government organizations, regulatory authorities, policymakers, researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies
- Manufacturers of biochip products who are looking for new avenues of revenue generation
Frequently Asked Questions (FAQ) :
The biochip market is growing at a CAGR of 11.5% over the forecast period.
The application of the biochip market Genomics, Proteomics, Drug Discovery and Development, In-Vitro Diagnostics, Disease Diagnostics, Agriculture
The top companies that hold the market share in biochip market are bioMerieux SA, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Fluidigm, Illumina, Inc., HORIBA, Ltd., PerkinElmer, Inc., QIAGEN, Randox Laboratories Ltd., and Thermo Fisher Scientific Inc.
Biochips form an exciting and emerging technology in the field of biotechnology and electronics. Development in the area of genomics, proteomics and pharmaceutical manufacturing is assisting scientists with new methods for understanding the complex biochemical processes in the cells; hence serving the larger goal of understanding and treating several diseases. Additionally, the semiconductor industry is steadily perfecting the skill of micro-miniaturization and merging this with biotechnology has led to the development of biochips that has enabled biotechnologists to condense the traditional sensing tools into smaller spaces.
Development of complete human genome sequence and intensive search for polymorphic variation are creating prerequisite markers required for elucidating genetic variability in drug response. Further improvement in sensitivity and precision of DNA biochip allows detailed and accurate analysis of the human genome. Such progress has the potential to improve healthcare management by improving the status of disease diagnosis, drug screening and targeted molecular therapy. Widespread use of biochips will also expand the application of pharmacogenomics to become an integral part of health management, and therapeutic monitoring, therefore ensuring better treatment outcomes and patient stratification.
Application of microarrays in genomics has expanded with technological evolution. Biochips are widely used in exon-based gene expression analysis, resequencing and genotyping applications, genome-wide localization and competitive genomic hybridization studies. Use of biochips is also expanding in improving the process of disease diagnosis, and toxicogenomics.
Governments and private organizations of several countries have increasingly become aware of the benefits associated with biotechnology and the potential in regenerative medicine, drug discovery, and development. Therefore, fuelled by the desire for new life science breakthroughs and innovation, the biotechnology industry has continued to witness substantial growth due to increased R&D investment. As reported in the BDO Biotech Briefing 2017, in the U.S., the average R&D spending across the mid-market biotechnology companies increased by 18% from average of 65.9 Mn (2015) to 80.6 Mn (2016). Growth in R&D spending is, therefore, a prominent factor that explains the recent uptick in innovation across all the fields of biotechnology. Small biotech companies (revenue less than 50 Mn) increased R&D investment by 24%, and 20% growth was witnessed in large companies. Approximately 94% of the patents granted by the US Patent and Trademark Office comes from the G20 countries.
DNA biochip presents several advantages owing to its miniaturization and integration features, and is becoming a common tool used in life sciences, drug screening and diagnostic applications. They can be used for pharmacogenomics which comprise profiling of gene expression, measuring & analyzing regulated genes under different conditions and genotyping, detecting polymorphisms or mutations in a gene sequence. A significant use for DNA biochip is in molecular diagnostics, which include genetic screening, pathogens recognition, & molecular oncology (e.g., cancer diagnosis). Biochip can also be used for drug screening, chemical synthesis & many other applications in high-throughput form.
DNA chip is made up of a solid support system usually silicon or glass on which the DNA is arranged in a grid fashion. The probe comprises single gene and is known as a DNA spot. The technology is evolved from the southern blotting technique in which the DNA fragments are attached to a solid substrate and probed by using a known DNA sequence. DNA chips are of two types, the cDNA based microarray and oligonucleotide based microarray. In the last two decades, the DNA chips are being utilized in research studies for drug discovery, disease diagnosis, gene expression profiling, proteomics, DNA sequencing, alternative splicing detection and toxic genomics.
Breakthrough innovation was achieved by the creation of mitochondrial DNA chips, which are employed in forensic cases containing hair samples as the only physical evidence. Mitochondrial DNA is inherited maternally, thus finding prominence in the identification of human remains with a known sample from maternal relative. The limitations associated with DNA chips are huge cost incurred during its manufacturing, analysis of multiple results generated in short span and the short shelf life of DNA chips.
Protein chips are microarrays of proteins on a solid surface such as membrane, slides, microtitre plates or beads. Nitrocellulose slides are mostly preferred due to its high protein binding capacity. The solid surface is then coated by immobilizing agents such as hydrophilic polymers, gold or with polyacrylamide gels. After the immobilization of proteins, they can be used as a probe for a variety of activities. The signals are measured by employing fluorescent dyes or radioisotope labels.
Currently, two types of protein chips are available such as functional protein microarrays and analytical protein microarrays. Functional protein microarrays find application in quarters such as biochemical activity, protein interaction and immune responses. Analytical protein microarrays are well known for its multiplexed detection technology. During the forecast period, the protein chips segment will show impressive growth due to its adoption in pathogen detection and food industries. The limitations associated with protein chips are involvement of multiple tedious steps during manufacture, protein instability, low solubility and formation of inclusion bodies during substrate interaction renders the protein chips unreliable and inconsistent with sample analysis.
In 2018, North America was identified as the largest market for biochips holding over 35% market share globally. The increase in demand for DNA chips coupled with advanced diagnostic and molecular analysis are the prime factors contributing to the growth of biochips market in North America.
Rising adoption of biochips for personalized medicine, growing applications in veterinary, and technological assessments in advanced biomaterial and sensors are the major drivers for the biochips market. Outsourcing of bio-processing activities of pharmaceutical and biotechnology companies, strict regulations, high instrumentation expenses in the developing markets may hinder the market development to a certain extent during the forecast period. It is projected that the biochips market in Asia Pacific and Europe will witness rapid growth in the given period of forecast. The increase in biopharmaceutical companies from Asia Pacific, especially countries such as China, South Korea and India coupled with the prevalent trend of outsourcing of research processes to Asian countries for various biochip analysis methodologies and applications would drive the market.
The market players in the region continue to focus on research & development activities to innovate biochip applications and instrumentation, diversity of different analysis methods such as electrophoresis, luminescence, mass spectrometry and their cellular interactions to develop different applications for more specific and effective molecular analysis and advanced bioscience research. Development and innovation in the tools used for biochips have enabled bio-researchers to study the fabrication methods at even higher specificities, thus assisting in increasing the number of different applications of biochips and related discoveries. With increased preference towards the use of DNA and enzyme chips, the market is likely to experience more investments in the global market to support the overall biochips industry.
The North America biochips market is driven by the applications in drug discovery and development, higher preference for compact biochips, shift towards use of live model systems for drug discovery and evaluation, and growing demand for advanced research in cancer and diagnostics industry. In the U.S., rising trends in contract manufacturing and research to cater ever-increasing demands of the healthcare sector with respect to advanced diagnostics & treatment options will further fuel the biochips market in North America. Increased medical implementation of biochips can be seen as glucose detector, as an oxygen sensor and blood pressure sensor. To increase competitive edge, top key manufacturers have concentrated on the practice of partnerships & collaborations, adoption of new techniques and launch of medical technology products. The evolving utilization of biochips in the therapeutic division for research (drug discovery), disease treatment, and cancer diagnostics has also shown promising growth for biochip industry on a global scale.
Ascend in the integration of miniaturized and biochip devices for natural or biochemical responses in diagnostics, therapeutic applications, treatment, and research further going to spur revenue growth during the forecast period in the U.S. The inclination for minimized biochips over ordinary complex instruments shows higher acknowledgment by the end users in the U.S., it can bring numerous biochip applications in a quick and cheap way. Major players have been profiting from expanding interests in pharmaceutical sector. However, for new businesses, administrative hindrances and regulations by the domestic governments and authorities represent an extreme challenge. Nevertheless, the U.S. biochips market is expected to expand at a favourable pace during the forecast period.
.png "Global Biochips Market by Region, 2015-2025 (USD Million)")
